Remove 2015 Remove Clinical Trials Remove Epilepsy
article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).

article thumbnail

Global Medical Cannabis Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com

Cannabis Law Report

The global medical cannabis market exhibited strong growth during 2015-2020. Clinical trials, research and development (R&D) activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market. during 2021-2026. Companies Mentioned. Canopy Growth Corporation. Chronic Pain.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Using Cannabis for ALS: Benefits, Research and Best Strains

Greencamp

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94
article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.

article thumbnail

How medical marijuana could help you find the ‘new you’ in the New Year

Canna Care Docs

The evidence of its effectiveness is clear, as clinical trials have shown a significant reduction in pain for patients suffering with neuropathic pain from multiple sclerosis, pain from rheumatoid arthritis, cancer pain, HIV or complex regional pain syndrome, headaches and menstrual pain, among other potential uses. Chronic pain.

article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).